Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study

Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study

Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact t...

Full description

Bibliographic Details
Main Authors: Jin-Ge Zhao, Jian-Dong Liu, Peng-Fei Shen, Xin Tang, Guang-Xi Sun, Xing-Ming Zhang, Jun-Ru Chen, Kun-Peng Shu, Ming Shi, Hao Zeng
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Asian Journal of Andrology
Subjects:
abiraterone; antiandrogen; castration-resistant prostate cancer; flutamide
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=545;epage=550;aulast=Zhao

Similar Items

Similar Items